The enigma of young age.

[1]  I Persson,et al.  The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.

[2]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[3]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Allred,et al.  Breast cancer outcome and predictors of outcome: are there age differentials? , 1994, Journal of the National Cancer Institute. Monographs.

[5]  I. Ellis,et al.  Early-onset breast cancer--histopathological and prognostic considerations. , 1997, British Journal of Cancer.

[6]  F. Cavalli,et al.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. , 1998, European journal of cancer.

[7]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[8]  P. Sismondi,et al.  Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gray,et al.  Adjuvant therapy for very young women with breast cancer: need for tailored treatments. , 2001, Journal of the National Cancer Institute. Monographs.

[10]  J. Cuzick,et al.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Gnant,et al.  Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. , 2002, Clinical breast cancer.

[12]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[13]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[15]  M. Gnant,et al.  Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Love,et al.  Young age as an adverse prognostic factor in premenopausal women with operable breast cancer. , 2002, Clinical breast cancer.

[17]  L Collette,et al.  Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? , 2003, European journal of cancer.

[18]  Yudong D. He,et al.  A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.

[19]  S. Martino,et al.  Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[21]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[22]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[23]  W. Parulekar,et al.  Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Aebi.  Special issues related to the adjuvant therapy in very young women. , 2005, Breast.

[25]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Young age is a poor prognostic factor in women with stage I breast cancer , 2006 .

[27]  A. Luini,et al.  Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Singletary,et al.  Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Young age is not an independent prognostic factor , 2006 .